BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2366 related articles for article (PubMed ID: 8331230)

  • 41. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose.
    Lapela M; Grénman R; Kurki T; Joensuu H; Leskinen S; Lindholm P; Haaparanta M; Ruotsalainen U; Minn H
    Radiology; 1995 Oct; 197(1):205-11. PubMed ID: 7568825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
    Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
    Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
    Friess H; Langhans J; Ebert M; Beger HG; Stollfuss J; Reske SN; Büchler MW
    Gut; 1995 May; 36(5):771-7. PubMed ID: 7797130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose.
    Kole AC; Nieweg OE; van Ginkel RJ; Pruim J; Hoekstra HJ; Paans AM; Vaalburg W; Koops HS
    Ann Surg Oncol; 1997 Jan; 4(1):57-63. PubMed ID: 8985518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Value of whole-body FDG PET in management of lung cancer.
    Higashi K; Matsunari I; Ueda Y; Ikeda R; Guo J; Oguchi M; Tonami H; Yamamoto I
    Ann Nucl Med; 2003 Feb; 17(1):1-14. PubMed ID: 12691125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography.
    Wahl RL; Hutchins GD; Buchsbaum DJ; Liebert M; Grossman HB; Fisher S
    Cancer; 1991 Mar; 67(6):1544-50. PubMed ID: 2001543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
    Cook GJ; Houston S; Barrington SF; Fogelman I
    J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) whole body scan (WBS) in the staging and follow-up of cancer patients: our first experience.
    Ferlin G; Rubello D; Chierichetti F; Zanco P; Bergamin R; Trento P; Fini A; Cargnel S
    Tumori; 1997; 83(3):679-84. PubMed ID: 9267488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
    Crowe JP; Adler LP; Shenk RR; Sunshine J
    Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
    Kubota K
    Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.
    Yasuda S; Raja S; Hubner KF
    Surg Today; 1995; 25(3):261-4. PubMed ID: 7640457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 119.